Gynesonics added another $6.3 million to its coffers as it looks to bring the latest iteration of its VizAblate fibroid device to the U.S. market.
Redwood City, Calif.-based Gynesonics’ VizAblate is a minimally invasive device that uses ultrasound imaging and radiofrequency ablation to remove fibroid tumor from the uterus as an alternative to hysterectomy.
Help employers find you! Check out all the jobs and post your resume.
